Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?

References

• Esserman LJ, Joe BN. Clinical features, diagnosis and staging of newly diagnosed breast cancer. UpToDate. [cited 2015 Nov 30]. Available from: www.uptodate.com
   Google Scholar
• Zanaradi E, Bregni G, De Braud F, et al. Better together: targeted combination therapies in breast cancer. Semin Oncol. 2015;42:887–895.
   PubMed Web of Science ®Google Scholar
• Ellis M, Naughton MJ, Ma CX. Treatment approach to metastatic hormone receptor-positive breast cancer: endocrine therapy. UpToDate. [cited 2015 Dec 10]. Available from: www.uptodate.com
   Google Scholar
• Rossi L, Pagani O. The modern landscape of endocrine therapy for premenopausal women with breast cancer. Breast Care (Basel). 2015;10:312–315.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26:5.
   Web of Science ®Google Scholar
• Bartczak M, Sałagacka A, Mirowski M, et al. K-RAS gene – prognostic and predictive factor in colon cancer. NOWOTWORY J Oncol. 2010;60:147–156.
   Google Scholar
• Goodwin PJ. Obesity and endocrine therapy: host factors and breast cancer outcome. Breast. 2013;22:44–47.
   PubMed Web of Science ®Google Scholar
• Wolters R, Schwentner L, Regierer A, et al. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat. 2012;131:925–931.
   PubMed Web of Science ®Google Scholar
• Ligibel JA, Winer EP. Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012;30:2940–2942.
   PubMed Web of Science ®Google Scholar
• Wysokinski D, Blasiak J, Pawlowska E. Role of RUNX2 in breast carcinogenesis. Int J Mol Sci. 2015;16(9):20969–20993.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Konigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653–2659.
   PubMed Web of Science ®Google Scholar
• Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627–635.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Stoger H, Dubsky P, et al. Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer. 2013;108:1408–1414.
   PubMed Web of Science ®Google Scholar
• Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28:3411–3415.
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Stoger H, et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomized ABCSG-6a trial. Br J Cancer. 2013;109:589–596.
   PubMed Web of Science ®Google Scholar
• Takada M, Saji S, Masuda N, et al. Relationship between body mass index and pre-operative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast. 2012;21:40–45.
   PubMed Web of Science ®Google Scholar
• Seynaeve C, Hille E, Hasenburg A, et al. The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM study. Cancer Res. 2011;70:2–3.
   Google Scholar
• Ewertz M, Gray KP, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol. 2012;30:3967–3975.
   PubMed Web of Science ®Google Scholar
• Sendur MA, Aksoy S, Zengin N, et al. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer. 2012;107:1815–1819.
   PubMed Web of Science ®Google Scholar
• Folkerd EJ, Dixon JM, Renshaw L, et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30:2977–2980.
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Wieand K, Johnson KA, et al. Obesity, tamoxifen use, and outcomes in women with estrogen receptor positive early-stage breast cancer. J Natl Cancer Inst. 2003;95:1467–1476.
   PubMedGoogle Scholar
• Longcope C, Baker R, Johnston CC. Androgen and estrogen metabolism: relationship to obesity. Metabolism. 1986;35:235–237.
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95:1218–1226.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Knöll D, Struck M, et al. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone sensitive early breast cancer treated with anastrozole. J Cancer Res Clin Oncol. 2014;140:159–166.
   PubMed Web of Science ®Google Scholar
• Elliott KM, Dent J, Stanczyk FZ, et al. Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer. Br J Surg. 2014;101:939–948.
   PubMed Web of Science ®Google Scholar
• Sini V, Lunardi G, Cirillo M, et al. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. Br J Cancer. 2014;110:1133–1138.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Konigsberg R, Hadji P, et al. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. Br J Cancer. 2013;109:1522–1527.
   PubMed Web of Science ®Google Scholar
• Diorio C, Lemieux J, Provencher L, et al. Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Res Treat. 2012;136(2):573–579.
   PubMed Web of Science ®Google Scholar
• Hubalek M, Oberguggenberger A, Beer B, et al. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. Clin Breast Cancer. 2014;14:291–296.
   PubMed Web of Science ®Google Scholar
• Bowers LW, De Angel R, Tekmal R, et al. Obesity-associated growth factor signaling upregulates aromatase expression and estrogen receptor activity in breast cancer cells. Cancer Res. 2012;72:3071.
   Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med. 2010;88:677–686.
   PubMed Web of Science ®Google Scholar
• Powell K. Obesity: the two faces of fat. Nature. 2007;447:525–527.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42–51.
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101:48–60.
   PubMed Web of Science ®Google Scholar
• Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer. 2003;10:331–345.
   PubMed Web of Science ®Google Scholar
• Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270:1491–1494.
   PubMed Web of Science ®Google Scholar
• Engels CC, de Glas NA, Sajet A, et al. The influence of insulin-like growth factor-1-receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: a Dutch TEAM substudy analysis. Mol Oncol. 2015;30:1–8.
   Google Scholar
• Bunnell BA, Flaat M, Gagliardi C, et al. Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008;45:115–120.
   PubMed Web of Science ®Google Scholar
• Strong AL, Strong TA, Rhodes LV, et al. Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Res. 2013;15:102.
   PubMed Web of Science ®Google Scholar
• Jin SJ, Jung JA, Cho SH, et al. The pharmacokinetics of letrozole: association with key body mass metrics. Int J Clin Pharmacol Ther. 2012;50:557–565.
   PubMed Web of Science ®Google Scholar
• Desta Z, Kreutz Y, Nguyen AT, et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther. 2011;90:693–700.
   PubMed Web of Science ®Google Scholar
• Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass index to diagnose obesity in the US adult population. Int J Obes (Lond). 2008;32:959–966.
   PubMed Web of Science ®Google Scholar